Kyle Z. Horvath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kyle Z. Horvath has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Barkhordar
Division of Pediatric Surgery Cedars‐Sinai Medical Center Los Angeles California USA
2 shared publications - Cameron Arkin
Division of Pediatric Surgery, Department of Surgery, Primary Children's Hospital University of Utah School of Medicine Salt Lake City Utah USA
2 shared publications - Catherine B. Beckhorn
Division of Pediatric Surgery, Department of Surgery, Duke Children's Hospital and Health Center Duke University Medical Center Durham North Carolina USA
2 shared publications Charbel Chidiac
Division of Pediatric Surgery, Department of Surgery Johns Hopkins University School of Medicine Baltimore Maryland USA
2 shared publicationsChloé Boehmer
Division of Pediatric General and Thoracic Surgery, Department of Surgery, Cincinnati Children's Hospital Medical Center University of Cincinnati College of Medicine Cincinnati Ohio USA
2 shared publicationsDafydd A. Davies
Division of Pediatric General and Thoracic Surgery, Department of Surgery, IWK Health Centre Dalhousie University Halifax Nova Scotia Canada
2 shared publications
Latest Publications
- 20 November 2026
- Published by Wiley in Pediatric Blood & Cancer
Indocyanine Green Assists in Identification of Solid Tumor Pulmonary Metastases
Background: The presence of pulmonary metastases reduces overall survival in patients with certain solid tumors; therefore, surgical clearance is crucial to cure for some types. This multi‐institutional prospective study sought to determine the utility and diagnostic accuracy of indocyanine green (ICG) for delineating pulmonary metastases in diverse pediatric, adolescent, and young adult solid cancers. Procedure: Thirteen member institutions of the Pediatric Surgical Oncology Research Collaborative administered preoperative ICG to patients undergoing pulmonary metastasectomy for primary or recurrent solid tumor malignancy (2019–2023). Surgeons reported their perspective on ICG utility for pulmonary metastasectomy following each operation. The diagnostic accuracy of ICG fluorescence to identify a pathologically confirmed tumor‐containing specimen was determined. Results: Of 829 specimens resected during 134 pulmonary metastasectomies (30.6% hepatic, 47.0% osteosarcoma, 17.2% non‐osteosarcoma‐type sarcomas [“other sarcomas”], 5.2% other non‐hepatic and non‐sarcoma tumor types [“other tumor types”]). Surgeons reported ICG as helpful in 77.6% of procedures. In 11.9% of cases, ICG identified viable metastases not visualized on preoperative imaging. Adjusted diagnostic accuracy and sensitivity (95% confidence interval [CI]) for metastases from all tumor types was 80.7% (77.9%–83.3%) and 82.5% (78.9%–85.8%), respectively. By primary tumor histology, adjusted accuracy and sensitivity (95% CI) were 83.2% (74.4%–89.9%), 46.7% (28.3%–65.7%) for metastases from other sarcomas, 80.6% (75.3%–85.2%), 95.6% (91.8%–98.0%) for hepatic tumors, 80.6% (76.6%–84.2%), 77.1% (71.4%–82.2%) for osteosarcoma, and 72.7% (49.8%–89.3%), 60.0% (26.2%–87.8%) for other tumor types. Conclusions: During pulmonary metastasectomy, adjusted diagnostic accuracy of ICG was 80.7%, and, importantly, 11.9% of metastasectomies contained viable tumors identified by ICG but not by preoperative imaging.
- 20 November 2026
- Published by Wiley in Pediatric Blood & Cancer
Indocyanine Green Assists in Identification of Solid Tumor Pulmonary Metastases
Background: The presence of pulmonary metastases reduces overall survival in patients with certain solid tumors; therefore, surgical clearance is crucial to cure for some types. This multi‐institutional prospective study sought to determine the utility and diagnostic accuracy of indocyanine green (ICG) for delineating pulmonary metastases in diverse pediatric, adolescent, and young adult solid cancers. Procedure: Thirteen member institutions of the Pediatric Surgical Oncology Research Collaborative administered preoperative ICG to patients undergoing pulmonary metastasectomy for primary or recurrent solid tumor malignancy (2019–2023). Surgeons reported their perspective on ICG utility for pulmonary metastasectomy following each operation. The diagnostic accuracy of ICG fluorescence to identify a pathologically confirmed tumor‐containing specimen was determined. Results: Of 829 specimens resected during 134 pulmonary metastasectomies (30.6% hepatic, 47.0% osteosarcoma, 17.2% non‐osteosarcoma‐type sarcomas [“other sarcomas”], 5.2% other non‐hepatic and non‐sarcoma tumor types [“other tumor types”]). Surgeons reported ICG as helpful in 77.6% of procedures. In 11.9% of cases, ICG identified viable metastases not visualized on preoperative imaging. Adjusted diagnostic accuracy and sensitivity (95% confidence interval [CI]) for metastases from all tumor types was 80.7% (77.9%–83.3%) and 82.5% (78.9%–85.8%), respectively. By primary tumor histology, adjusted accuracy and sensitivity (95% CI) were 83.2% (74.4%–89.9%), 46.7% (28.3%–65.7%) for metastases from other sarcomas, 80.6% (75.3%–85.2%), 95.6% (91.8%–98.0%) for hepatic tumors, 80.6% (76.6%–84.2%), 77.1% (71.4%–82.2%) for osteosarcoma, and 72.7% (49.8%–89.3%), 60.0% (26.2%–87.8%) for other tumor types. Conclusions: During pulmonary metastasectomy, adjusted diagnostic accuracy of ICG was 80.7%, and, importantly, 11.9% of metastasectomies contained viable tumors identified by ICG but not by preoperative imaging.
- Open Access
Indocyanine green assists with sentinel lymph node mapping in pediatric and adolescent patients: A Pediatric Surgical Oncology Research Collaborative prospective observational study
Background: Sentinel lymph node (SLN) biopsy is a critical staging tool in skin and soft tissue cancers. Although technetium lymphoscintigraphy is the most common adjunct, indocyanine green (ICG) demonstrates a promising alternative in pediatric, adolescent, and young adult (AYA) skin and soft tissue cancers. Methods and Objectives: Evaluate the safety and efficacy of ICG in SLN biopsy (SLNB) in diverse pediatric and AYA solid cancers in a multi‐institutional environment. This is a prospective, observational study conducted at 13 member institutions in the Pediatric Surgical Oncology Research Collaborative between 2019 and 2023. Eligible patients underwent SLNB for primary or recurrent solid skin and soft tissue tumors. Peritumoral ICG was administered intraoperatively. Outcomes included SLN detection rates, histopathology of excised specimens, and surgeon‐reported assessment of utility. Safety was assessed through adverse event reporting. Results: Forty SLNB procedures yielded 84 specimens: 13 melanoma (32.5%), 12 squamous cell carcinoma (30%), 11 non‐rhabdomyosarcoma soft tissue sarcoma (27.5%), two rhabdomyosarcoma (5%), one Ewing sarcoma (2.5%), and one malignant peripheral nerve sheath tumor (2.5%). Histologic evaluation identified 81 lymph nodes, 75 benign (89.3%) and six malignant (7.1%); three specimens were adipose tissue (3.6%). Of 81 lymph nodes, 76% were ICG‐positive. ICG had a sensitivity of 79.5%, a specificity of 33%, and a positive predictive value of 96%. All malignant nodes were ICG‐avid. There were no adverse reactions to ICG at 30 days. Conclusions: ICG is a safe and effective adjunct for SLNB in pediatric and AYA soft tissue and skin malignancies.
Open AccessIndocyanine green assists with sentinel lymph node mapping in pediatric and adolescent patients: A Pediatric Surgical Oncology Research Collaborative prospective observational study
Background: Sentinel lymph node (SLN) biopsy is a critical staging tool in skin and soft tissue cancers. Although technetium lymphoscintigraphy is the most common adjunct, indocyanine green (ICG) demonstrates a promising alternative in pediatric, adolescent, and young adult (AYA) skin and soft tissue cancers. Methods and Objectives: Evaluate the safety and efficacy of ICG in SLN biopsy (SLNB) in diverse pediatric and AYA solid cancers in a multi‐institutional environment. This is a prospective, observational study conducted at 13 member institutions in the Pediatric Surgical Oncology Research Collaborative between 2019 and 2023. Eligible patients underwent SLNB for primary or recurrent solid skin and soft tissue tumors. Peritumoral ICG was administered intraoperatively. Outcomes included SLN detection rates, histopathology of excised specimens, and surgeon‐reported assessment of utility. Safety was assessed through adverse event reporting. Results: Forty SLNB procedures yielded 84 specimens: 13 melanoma (32.5%), 12 squamous cell carcinoma (30%), 11 non‐rhabdomyosarcoma soft tissue sarcoma (27.5%), two rhabdomyosarcoma (5%), one Ewing sarcoma (2.5%), and one malignant peripheral nerve sheath tumor (2.5%). Histologic evaluation identified 81 lymph nodes, 75 benign (89.3%) and six malignant (7.1%); three specimens were adipose tissue (3.6%). Of 81 lymph nodes, 76% were ICG‐positive. ICG had a sensitivity of 79.5%, a specificity of 33%, and a positive predictive value of 96%. All malignant nodes were ICG‐avid. There were no adverse reactions to ICG at 30 days. Conclusions: ICG is a safe and effective adjunct for SLNB in pediatric and AYA soft tissue and skin malignancies.
- 13 September 2024
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 60 (1) , 161924
Assessing the Diagnostic Accuracy of TI-RADS in Pediatric Thyroid Nodules: A Multi-institutional Review
- 13 September 2024
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 60 (1) , 161924
Assessing the Diagnostic Accuracy of TI-RADS in Pediatric Thyroid Nodules: A Multi-institutional Review
- 18 March 2022
- Published by Elsevier in Journal of Surgical Research
- Vol. 275, 308-317
Implementation of a Level 1 Neuro Trauma Activation at a Tertiary Pediatric Trauma Center
- 18 March 2022
- Published by Elsevier in Journal of Surgical Research
- Vol. 275, 308-317
Implementation of a Level 1 Neuro Trauma Activation at a Tertiary Pediatric Trauma Center